Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9ULV1

UPID:
FZD4_HUMAN

ALTERNATIVE NAMES:
FzE4

ALTERNATIVE UPACC:
Q9ULV1; A8K9Q3; Q14C97; Q6S9E4

BACKGROUND:
The Frizzled-4 protein, identified by its alternative name FzE4, acts as a receptor in the Wnt signaling pathway, crucial for cellular processes including tissue morphogenesis and retinal vascularization. It mediates both Wnt-dependent and independent pathways, highlighting its versatility in cellular signaling.

THERAPEUTIC SIGNIFICANCE:
Linked to Vitreoretinopathy, exudative 1, Frizzled-4's involvement in retinal diseases underscores its potential as a therapeutic target. Exploring Frizzled-4's functions could lead to innovative treatments for retinal vascular disorders, offering hope for patients with these challenging conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.